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Abstract:	   	  
We	   describe	   a	   62-­‐year-­‐old	   patient	   with	   a	   4-­‐year	   history	   of	   myelodysplasia	   who	   later	   developed	  
striking	  features	  that	  included	  massive	  splenomegaly,	  rapidly	  evolving	  visual	  loss	  and	  a	  sensorimotor	  
polyneuropathy.	  This	  led	  us	  to	  consider	  the	  diagnosis	  of	  haemophagocytic	  lymphohistiocytosis	  (HLH).	  
Upon	   further	   investigation,	   we	   found	   that	   he	   fulfilled	   the	   necessary	   diagnostic	   criteria	   for	   HLH,	  
including	  the	  presence	  of	  haemophagocytosis	  of	  erythroid	  precursors	  on	  bone	  marrow	  smear.	   	  
	  




Haemophagocytic	  lymphohistiocytosis	  (HLH)	  is	  defined	  by	  the	  association	  of	  several	  criteria	  including	  
fever,	   splenomegaly,	  bicytopenia	  or	  pancytopenia,	  hypofibrinogenaemia	  hypertriglyceridaemia	  and	  
haemophagocytosis	   on	   examination	   of	   bone	   marrow	   or	   spleen.	   Additional	   criteria	   include	   low	  
natural	  killer	  (NK)-­‐cell	  activity,	  hyperferritinaemia	  and	  high	  soluble	  interleukin-­‐2-­‐receptor	  levels1.	   	  
HLH	  can	  be	  fatal	  if	  allogeneic	  stem	  cell	  transplantation	  (SCT)	  is	  not	  performed.	  Mortality	  rates	  of	  52%	  
have	  been	  reported	  in	  secondary	  forms	  of	  HLH.	  Available	  treatment	  options	  include	  cytotoxic	  agents,	  
corticosteroids,	  immunosuppressive	  therapy	  and	  SCT2.	   	   	  
HLH	   may	   be	   idiopathic	   or	   it	   may	   be	   associated	   with	   several	   entities	   characterised	   by	   immune	  
dysregulation.	   Secondary	   forms	   of	   HLH	   may	   occur	   in	   the	   context	   of	   chronic	   infections	   and	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We	   report	   the	  case	  of	  a	  62-­‐year-­‐old	  patient	  with	  myelodysplasia	  who	  developed	  unusual	   features	  
and	  eventually	  fulfilled	  the	  criteria	  for	  HLH.	   	  
	  
Case	  report	   	  
A	  62-­‐year-­‐old	  patient	  had	  a	  4-­‐year	  history	  of	  refractory	  cytopenia	  with	  multilineal	  dysplasia.	  He	  also	  
had	   a	   mild	   monoclonal	   IgG-­‐lambda	   gammopathy.	   He	   was	   being	   treated	   with	   erythropoietin	   and	  
G-­‐CSF	  analogues.	  One	  year	  earlier	  he	  had	  developed	  papilloedema	  and	  impaired	  vision.	  He	  improved	  
with	  prednisone	  60	  mg/day	  and	  progressive	  tapering	  but	  his	  vision	  deteriorated	  one	  month	  prior	  to	  
admission	  and	  he	  had	  to	  be	  placed	  on	  the	  initial	  dose	  again.	   	  
He	   presented	  with	   a	   4-­‐day	   history	   of	   pain	   and	   swelling	   in	   his	   left	   leg.	   Deep	   vein	   thrombosis	  was	  
diagnosed	   through	   ultrasonography.	   He	   was	   placed	   on	   anticoagulation	   with	   dalteparin	   and	   the	  
growth	  factors	  were	  temporarily	  withheld.	   	  
A	  CT	  scan	  of	  the	  chest	  and	  abdomen	  was	  performed	  to	  rule	  out	  an	  occult	  neoplasm.	  It	  demonstrated	  
a	  splenomegaly	  of	  17.4	  cm	  that	  had	  progressively	  increased	  over	  the	  last	  year.	   	  
Treatment	   with	   growth	   factors	   was	   resumed	   72	   h	   after	   admission	   and	   we	   initially	   obtained	   an	  
adequate	  response.	  However,	  over	  the	  course	  of	  a	  month	  we	  observed	  progressive	  worsening	  of	  his	  
pancytopenia.	   	  
A	   bone	   marrow	   aspirate	   demonstrated	   a	   hypercellular	   marrow	   with	   significant	   dyspoiesis	   in	   the	  
erythroid	  and	  megakaryocytic	  series.	  While	  this	  smear	  ruled	  out	  progression	  to	  acute	  leukaemia,	   it	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Due	   to	   his	   worsening	   thrombocytopenia,	   with	   a	   platelet	   count	   that	   reached	   5000/mm3,	   we	  
withdrew	  treatment	  with	  dalteparin.	  Two	  weeks	  later	  he	  began	  to	  complain	  of	  pain	  and	  swelling	  in	  
his	  left	  calf.	  Ultrasonography	  confirmed	  a	  new	  deep	  vein	  thrombosis.	  We	  resumed	  anticoagulation.	   	  
The	  patient	  developed	  recurrent	  respiratory	  infections.	  A	  chest	  X-­‐ray	  revealed	  a	  cavitating	  lesion	  in	  
the	   right	   lower	   lobe.	   Pseudomonas	   aeruginosa	   was	   isolated	   from	   sputum	   and	   he	   was	   placed	   on	  
meropenem	   and	   tobramycin	   (the	   patient	   had	   received	   tobramycin	   for	   3	   days	   at	   a	   dosage	   of	   200	  
mg/twice	   daily).	   Aspergillus	   fumigatus	   was	   later	   isolated	   from	   sputum.	   He	   responded	   well	   to	  
voriconazole	  and	  caspofungin.	   	  
Throughout	   his	   hospitalisation,	   his	   visual	   acuity	   deteriorated	   despite	   treatment.	   Marked	   muscle	  
wasting	  and	  progressive	  deafness	  also	  ensued.	  Orbital	  MRI	  ruled	  out	   leukaemic	  infiltration	  of	  optic	  
nerves	   and	   nerve	   conduction	   studies	   revealed	   a	   sensorimotor	   polyneuropathy.	   Evoked	   potential	  
testing	  was	  consistent	  with	  bilateral	  sensorineural	  hearing	  loss.	  
The	   patient	   progressively	  worsened	   and	   he	   reached	   a	   platelet	   count	   of	   7000/mm3.	   Anticoagulant	  
therapy	   was	   withdrawn	   due	   to	   bleeding	   risk.	   The	   patient	   died	   two	   months	   after	   admission.	   No	  




We	  describe	  a	  patient	  with	  severe	  myelodysplasia	  who	  had	  several	   remarkable	   features.	  He	  had	  a	  
rapidly	   evolving	   splenomegaly,	   progressive	   visual	   loss	   and	   a	   sensorimotor	   polyneuropathy.	   These	  
unusual	   features	   prompted	   us	   to	   consider	   the	   diagnosis	   of	   an	   associated	   HLH.	   This	   scenario	   has	  
rarely	  been	  described3.	   The	  diagnosis	   of	  HLH	   is	   based	  on	   several	   criteria	   [1],	  many	  of	  which	  were	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hypofibrinogenaemia	   and	   hypertriglyceridaemia.	   We	   also	   found	   haemophagocytosis	   of	   erythroid	  
precursors	   on	   bone	  marrow	   smear.	   Therefore,	   he	   fulfilled	   the	   five	   criteria	   required	   for	   diagnosis.	  
Another	   diagnostic	   criteria	   includes	   ferritin	   levels	   >500	   ng/ml.	   However,	   the	   patient	   had	  
hyperferritinaemia	  that	  did	  not	  reach	  this	  diagnostic	  threshold.	   	  
Splenomegaly	  is	  very	  uncommon	  in	  myelodysplasia,	  and	  its	  presence	  may	  indicate	  myelomonocytic	  
leukaemia,	  which	  was	   ruled	   out	   by	   bone	  marrow	   aspirate.	   Splenomegaly	  may	   constitute	   the	   first	  
sign	  of	  leukaemic	  transformation.	  It	  may	  also	  indicate	  extensive	  extramedullar	  erythropoiesis4.	  Given	  
the	  rarity	  of	  splenomegaly	  in	  myelodysplasia,	  this	  clinical	  feature	  would	  fit	  better	  with	  HLH.	   	  
Polyneuropathy	   has	   been	   more	   frequently	   reported	   in	   HLH	   than	   in	   myelodysplasia5.	   The	  
papilloedema	   in	   this	   patient	  was	   perhaps	   the	   first	   sign	   of	   optic	   neuritis.	   The	   progression	   of	   optic	  
nerve	   involvement	   was	   halted	   by	   prednisone	   therapy,	   but	   later	   flared	   up	   when	   prednisone	   was	  
tapered.	  MRI	   studies	   ruled	  out	   the	  presence	  of	   vascular	   lesions	  and	   leukaemic	   infiltration	  of	  optic	  
nerve	  sheets.	   	  
Visual	   impairment	   has	   rarely	   been	   described	   in	   myelodysplasia;	   it	   may	   be	   caused	   by	   anaemic	  
hypoxia	  and	  microvascular	  insufficiency.	  These	  mechanisms	  were	  probably	  not	  responsible	  for	  visual	  
loss	   in	   this	   patient	   since	   the	   optic	   neuritis	   was	   initially	   responsive	   to	   prednisone.	   Despite	   the	  
presence	   of	   a	  mild	  monoclonal	   IgG-­‐lambda	   gammopathy,	   there	  were	   no	   signs	   of	   a	   hyperviscosity	  
syndrome.	   	  
Another	   striking	   feature	   of	   this	   patient	   was	   the	   development	   of	   progressive	   deafness.	   A	   slight	  
hearing	   impairment	   existed	   before	   admission,	  which	  worsened	   after	   being	   placed	   on	   tobramycin.	  
Tobramycin	   was	   stopped	   after	   three	   days	   of	   treatment	   but	   hearing	   loss	   continued	   to	   progress	  
significantly.	   	  
Cranial	   neuropathies	   have	   been	   described	   in	   HLH.	   A	   retrospective	   study	   of	   patients	   with	   HLH	  
revealed	  that	  as	  many	  as	  73%	  had	  evidence	  of	  central	  nervous	  system	  (CNS)	  involvement	  at	  the	  time	  
of	  diagnosis5.	   	  
In	  summary,	  this	  patient	  developed	  clinical	  features	  compatible	  with	  HLH	  in	  the	  last	  year	  of	  his	  life.	  
When	  the	  diagnosis	  of	  HLH	  was	  considered,	  he	  had	  already	  developed	  lung	  aspergillosis	  and	  a	  severe	  
polyneuropathy.	  This	  highlights	  the	  importance	  of	  considering	  the	  diagnosis	  of	  HLH	  in	  patients	  with	  
myelodysplasia	  and	  unusual	  features.	   	  
	  
Learning	  Points	  
• Haemophagocytic	   lymphohistiocytosis	   (HLH)	   can	   be	   a	   rare	   complication	   of	   myelodysplastic	  
syndromes.	  
• HLH	  is	  ultimately	  fatal	  if	  timely	  allogeneic	  stem	  cell	  transplantation	  is	  not	  performed.	  
• This	   case	   highlights	   the	   importance	   of	   considering	   the	   diagnosis	   of	   HLH	   in	   patients	   with	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